Medibiofarma, S.L.

Based in Navarra, Spain, and co-founded by Rodolfo Rodríguez Iglesias (CEO and IP director) in 2016, Medibiofarma, S. L. operates as a biotechnology research company developing drugs and therapies for the treatment of cancer. In March 2022, the firm raised EUR 570,000 in grant funding led by investor Center for Technological & Industrial Development.

The clinical stage biotechnology company engages in research programs, based on the modulation of clinically validated therapeutic targets, providing disease-modifying treatments for conditions such as cancer, cognitive decline, and fibrosis. Medibiofarma mainly focuses on discovering and developing new chemical entities (NCEs) with clinical proof-of-concept data in human patients. The company strategically allocates internal resources to key areas such as drug design, medicinal and synthetic chemistry, in vitro pharmacology, intellectual property, clinical trials, and business development. Notable among its pipeline is MBF-118, a covalent partial agonist of the PPARγ nuclear receptor, a therapy for fibrosis in Crohn's disease.

Additionally, Medibiofarma's portfolio includes MBF-362, an EP4 receptor antagonist for cancer immunotherapy, MBF-015, a histone deacetylase inhibitor targeting synaptic loss in neurodegenerative diseases, and MBF-132, a selective histone deacetylase 8 inhibitor for fibrosis treatment.